CareDx Announces KidneyCare and Showcases Leadership in Transplantation at ATC
“Building on the momentum of AlloSure, there is incredible potential for KidneyCare to enable us to tailor treatment for kidney transplant patients. The value is not only to identify when there may be an issue, but to reduce immunosuppression in a subset of patients,” said Ram Peddi, MD, Transplant Nephrologist at
Seven leaders in transplantation will speak during the CareDx Lunch Symposium titled Better Transplant Outcomes Start with Better Transplant Surveillance, on
Matthew Weir, MD, University of Maryland Alexandre Loupy, MD, PhD, Paris Transplant Group Vikas Dharnidharka, MD, MPH, Washington University Daniel C. Brennan, MD, FACP, Johns Hopkins Hospital Stanley C. Jordan, MD, FASN, FAST, Cedars-Sinai Transplant Center Tarek Alhamad, MD, MS, FACP, FASN, Barnes Jewish Hospital, Washington Anthony Langone, MD, FAST, Vanderbilt University Medical Center
Correlation of Donor-Derived Cell-Free DNA with Histology and Molecular Diagnoses of Kidney Transplant Biopsies. I. Moinuddin,
Donor Derived Cell Free DNA is Associated with De-Novo Donor Specific Antibody (DSA) Responses. S. Jordan,
Elevated Donor Derived Cell Free DNA (dd-cfDNA) Levels in the Presence of Donor Specific Antibodies (DSA) Are a Strong Predictor of Antibody Mediated Rejection (ABMR) in Pediatric Renal Transplant Recipients. D. Puliyanda,
The Use of dd-cfDNA as a Predictive Tool for Outcome Decreased Kidney Function. T. Alhamad,
Donor-Derived Cell-Free DNA (dd-cfDNA) Course after Rejection in Pediatric Kidney Transplant Recipients. R. Swinford,
Donor-Derived Cell-Free DNA for Surveillance in Simultaneous Pancreas and Kidney Transplant Recipients, Can We Extrapolate from Kidney Transplant Alone? O. Olaitan,
Donor Derived Cell Free DNA (dd-cfDNA)
External Validation of Donor-Derived Cell-Free DNA to Detect Rejection in Kidney Transplant Recipients. E. Huang,
Gene Expression Profiling for Cardiac Transplant Recipients: Results from the Outcomes AlloMap Registry. S. Hall,
Reference Ranges Donor-Derived Cell-Free DNA in a Heart Transplant Population. A. Kao, Saint Luke’s
Subclinical Antibody Mediation Rejection in Stable Kidney Recipients with De Novo Donor Specific Antibodies and Correlation with Donor Derived Cell Free DNA Testing. A. Bregman,
Utility of AlloSure Monitoring in Simultaneous Kidney and Pancreas Recipients. J. Klein,
“The number of quality presentations at ATC highlights our commitment to furthering innovation in transplantation,” says
For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements, including statements regarding the Company’s participation at ATC. These forward-looking statements are based upon information that is currently available to
Chief Commercial Officer
Integrated Corporate Relations, Inc.
Source: CareDx, Inc.